iHub News
3月前
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket tradingMarch 18, 2026 11:09 AM
IH Market News
InspireMD Inc. (NASDAQ:NSPR) reported stronger-than-expected fourth-quarter results for 2025, beating both earnings and revenue forecasts as sales accelerated following the U.S. launch of its CGuard Prime device.The company posted earnings per share of -$0.14 for the quarter, outperforming analyst expectations of -$0.19. Revenue reached $3.15 million, well above the forecast of $2.32 million. Following the announcement, InspireMD shares climbed about 12.8% in premarket trading to roughly $2.02.
Revenue growth driven by U.S. market
Total revenue rose 62% year over year to about $3.1 million, up from $1.9 million in the same quarter of 2024. The increase was largely fueled by the commercial rollout of the CGuard Prime carotid stent in the United States after receiving FDA approval in June 2025.The company said the shift toward higher U.S. sales improved its revenue mix and helped boost margins. U.S. revenue reached approximately $866,000 during the quarter, representing a 74% sequential increase.Gross profit totaled about $1.2 million, equivalent to 37.5% of revenue.For the previous twelve months through the third quarter of 2025, InspireMD reported total revenue of $7.78 million with a gross margin of roughly 25%. The company also reported a strong liquidity position, with a current ratio of 6.51, indicating that liquid assets significantly exceed short-term liabilities.
Market reaction
Investors reacted positively to the results, sending the stock higher in premarket trading after the announcement. The move reflected confidence in the company’s ability to grow revenue and expand in the U.S. market following regulatory approval of its flagship device.
Outlook and product development
Looking ahead, InspireMD expects continued revenue growth supported by the expansion of the CGuard Prime platform in the United States.The company is also working on a next-generation delivery system designed to improve technical performance and ease of use. That product is expected to be introduced in the fourth quarter of 2026.Analysts have recently revised their earnings estimates upward, and current price targets range between $4 and $6 per share.“Our Q4 results reflect the successful execution of our strategy to penetrate the U.S. market with CGuard Prime, and we are excited about the future growth opportunities as we continue to expand our product offerings and market presence,” said CEO Marvin Slosman.
Risks and challenges
Despite the strong quarterly performance, several risks remain. Delays in regulatory approvals for future products could slow growth, while increasing competition in the carotid intervention market may pressure margins. Supply chain disruptions could also affect manufacturing and delivery timelines, and broader economic conditions may influence healthcare spending.
Focus on expansion strategy
During the earnings call, analysts asked about the timeline for FDA approval of the TCAR-indicated CGuard Prime stent, which the company expects in the third quarter of 2026. Executives also addressed plans for managing operating expenses while expanding in the U.S. market, emphasizing a measured growth strategy aimed at balancing expansion with financial discipline.InspireMD stock price
Original: InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading
PennyPusher786
11月前
STAY AWAY FROM THIS TICKER, IT'S A DUMP... FDA APPROVAL OR NOT, Look at the past few trading years... Even if it goes up to $3 to $4 in the coming days... IT'S ABSOLUTE GARBAGE, either they're dumping their own shares or shareholders are dumping in After Hours, but I've been watching it since the dump from $4... Each time it grows a few cents, someone dumps it right back a few cents.
Keep your money safe and away from garbage like this
TheFinalCD
11月前
The Company’s announcement of FDA approval of the CGuard Prime Carotid Stent System triggers the second of four milestone-driven warrant tranches pursuant to the private placement financing of up to $113.6 million announced in May 2023. Gross proceeds from this warrant tranche are expected to be $17.9M if exercised in full. Proceeds, if any, will be used to support the imminent commercial launch of the CGuard Prime Carotid Stent System in the United States, initiating new regulatory pathways for advanced applications of our CGuard stent platform, and developing new products, while at the same time continuing to develop our business outside of the United States. Warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board members.
https://finviz.com/news/87528/inspiremd-announces-fda-approval-for-cguard-prime-carotid-stent-system-for-the-prevention-of-stroke
timberwolf7
2年前
Own shares, now in it for the run to the approval decision.
One of my remaining questions was, what kind of 'revenue' stream
do they see possible.
And if you get a chance, go to their website and listen to the webcast
of the QTRLY call they just had.
Kind of confirms this could see the share price at least double, which is my
'goal', and likely some more. $10/sh could even be in play although
one has to acknowledge, the 'markey' they are selling into has 'limitations' in terms
of how many 'end users' there is that could benefit from their design. Then there is
the question of, how much of the market will their design capture from the existing
that remains to be answered.
Disclaimer: own shares, in it now for the fda decision
Value_Investor
2年前
NSPR should crash to $0.258048 to be fair considering its recent Over Triple Super-Heavy Huge OS Dilutions --- from 8M shares (when it hit $0.8064) to over 25M shares now! The recent low was $0.8064 anyway!
Sell this Pos Scam at the bids ASAP before it is too late! Then use all the cash proceeds to buy its Mostly Valuable NASDAQ EV peers (such as KXIN: Super-Ridiculous-Low $4,044,292 Market Value with Huge BV/PPS Ratio 12.121 v.s. NSPR has Super-Ridiculous-High $98,970,584 Market Value with Super Tiny BV/PPS Ratio 0.625) to recover all the Huge Losses here! Note, KXIN ever soared to $0.6 in Premarket session just a few months ago!
The Book Value here has already crashed down 75% while the Cash Value here has already crashed down 80% since NSPR hit its recent low $0.8064!
So, sell NSPR ASAP before it creates A Series Of New Lows until it hits $0.258048 in the coming weeks/months...
Monksdream
3年前
InspireMD Inc NASDAQ: NSPR
GoSymbol lookup
Health Care : Health Care
Equipment & Supplies | Small Cap Value | Based in IsraelCompany profile
InspireMD, Inc. is a medical device company. The Company is focusing on the development and
commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary
disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in
stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet
and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
timberwolf7
3年前
Anything is possible, but my 1st target price range is $3 - 4, maybe $5.
Reasons:
1. established competition, going to have to demo they are 'worth' being the one 'desired'
2. non-US based company. Will the market embrace them, give them a favorable share price
And of course, is WHEN is it 'possible' and that won't be until the end of the Ph 3 monitoring period is complete in my estimation. Which of course is into early 2024
But in the act of disclosure, just starting to accumulate shares figuring a 2-3x return from this price range would be pretty darn good.
timberwolf7
4年前
Challenges
What I THINK I know:
-1st qtr 2023, expected to complete enrollment
-1st qtr 2024 timeframe: end of the 12 month follow up monitoring
-2nd qtr 2024 (maybe??): PH 3 trial results
-9 months or so later: up for an FDA decision, so likely at the earliest, end of 2024 for the approval decision (??) 2+ YEARS from now
-still working to expand sales in overseas markets, but realistically, needs the US market approval
That said, then there is the bigger challenge to come and that is, breaking in/capturing market share from some established big market players who
i doubt will easily see their revenue stream 'interrupted' by an upstart. So the question will end up being one of, is this that much better than whats on the market NOW. Will it be that much better that a shift will occur simply because of the advantages/benefits of the design or will the market say, what we have is 'good enough' and the design is a tough sell, slow to gain market share if any.
As a disclaimer: I finally bought a few thousand shares at $1.14. And I plan to add more simply for the PR events to come (ie, completed enrollment, any planned data releases, NDA filing, et al cause they do get the markets attention. So while I expect there to be opportunities to see gains develop from this price level, I am not sold that this WILL get a good toe hold in the US market at this point in time. But given the low share count, I do see a move to $4-5/sh from this price level as achievable. Which is why I wanted 'some shares' before I get surprised by a jump for something I didn't see coming.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
conix
5年前
メールアドレスで登録
